Smart CAR-T cells cleared diffuse midline glioma in mice — not yet in people
The full story behind my Short: UCSF B-SYNC CAR-T cells activate only in the brain (brevican sensor) and cleared DMG in mice; cells persisted past 70 days. Human trial at UCSF may begin as early as April 2027. Science Translational Medicine, 28 Oct 2026.
MICE ONLY. This therapy has not been tested in people. Promising lab results are not a treatment offer. This page is not medical advice — talk to an oncology team.
The short version
UCSF scientists engineered B-SYNC CAR-T cells that stay dormant until they sense brevican (a brain protein), then attack tumour markers shared by diffuse midline glioma (DMG). In mice with human DMG cells, the therapy cleared tumours where standard CAR-T failed [1][2][3].
What they found
With intracerebroventricular delivery, tumours cleared in every mouse tested in two models. Nearly seven weeks later a second implantation was rejected; cells were still functional past 70 days. Activity outside the brain did not express the CAR as designed. Paper in Science Translational Medicine (28 Oct 2026); authors include Lakshmanachetty, Okada, Lim, Mueller [1][2].
Limits and caveats
- Mice only. Not tested in humans yet.
- Trial not open. May begin as early as April 2027 at UCSF — timing can slip.
- DMG remains devastating. Children almost always die within a year with current care [1].
- Not medical advice. Families should speak with their oncology team.
Watch the Short
Why it matters
DMG has almost no good options. A brain-restricted CAR-T that works in mice is an important lab step — and only that — until human data exist.
Full narration (transcript)
Smart CAR-T cells that switch on only in the brain cleared a deadly childhood brain cancer — in mice. UCSF's B-SYNC therapy stays dormant until it senses a brain protein called brevican, then attacks tumour markers. The target was diffuse midline glioma — D M G — which infiltrates the brainstem. Children almost always die within a year. In mice with human tumour cells, B-SYNC cleared the cancer. Standard CAR-T cells did not. Given into the brain, it cleared tumours in every mouse tested in two models. Nearly seven weeks later, a second dose of cancer cells was rejected. Cells were still patrolling past 70 days. This is mice only. It has not been tested in people yet. A human trial at UCSF may begin as early as April 2027. The paper is in Science Translational Medicine. This isn't medical advice. Families facing this diagnosis should talk to their oncology team. Follow the link to the main website for much deeper information.
Sources
- [1] UCSF News, 28 Oct 2026 (Levi Gadye). https://www.ucsf.edu/news/2026/10/432911/smarter-car-t-cells-could-beat-deadly-pediatric-brain-cancer
- [2] News-Medical, 28 Oct 2026. https://www.news-medical.net/news/20261028/UCSF-scientists-develop-smart-CAR-T-cells-to-fight-childhood-brain-tumors.aspx
- [3] Lakshmanachetty S et al. B-SYNC CAR-T for DMG. Science Translational Medicine, 28 Oct 2026. https://www.science.org/journal/stm
Credits
Images via Wikimedia Commons (illustrative unless stated): CAR T-Cell Therapy.jpg (National Cancer Institute (NCI), Public domain); Adoptive T-cell therapy.png (Simon Caulton, CC BY-SA 3.0); Diffuse midline glioma MRI.jpg (Huang T., Garcia R., Qi J., Lulla R., Horbinski C., Behdad A., Wadhwani N., Shilatifard A., James C., Saratsis A. M., CC BY 4.0); Brain MRI glioma 048.jpg (Nevit Dilmen (talk), CC BY-SA 3.0); Human brainstem anterior view.JPG (John A Beal, PhD Dep't. of Cellular Biology & Anatomy, Louisiana State University Health Sciences Center Shreveport, CC BY 2.5); CAR T cell manufacturing and therapy.webp (Mohsen Sheykhhasan and Hamed Manoochehri, CC BY 4.0); Westgate Microscopy t-lymphocytes.jpg (Cannons Law Firm, Glasgow, UK, CC BY 4.0). On-screen graphics: own.
AI voice note: the narration in the Short is an AI clone of my own voice (Chatterbox TTS by Resemble AI, MIT licence), used with my consent. I wrote the script and checked the figures against the sources above.
This page is general information, not medical or dental advice. Please talk to a doctor, dentist or pharmacist about your own health.